bioAffinity Technologies Inc
The company maintains a strong liquidity position with $6.45 million in cash and equivalents, representing 58.8% of total assets. Its debt-to-equity ratio of 0.11 indicates a conservative capital structure, with long-term debt accounting for just 7.5% of total liabilities. The current ratio of 2.6 suggests the company can cover short-term obligations twice over, though negative operating cash flow of -$9.33 million and free cash flow of -$14.47 million highlight ongoing cash burn. Profitability metrics are sharply negative, with a return on equity of -204.87% and return on assets of -136.03%. These figures fall well below the industry median for medical equipment firms, which typically report positive ROE and ROA in the 5-15% range. Gross margin of 31.4% is in line with industry norms, but operating margin of -171.7% and net margin of -242.0% indicate severe cost overruns. The company operates as a single-segment business with 100% revenue concentration in its diagnostic products division. Geographic exposure is not disclosed in the latest filings, but the company is incorporated in the United States and maintains operations in Canada. No material revenue concentration by geograp
Business. bioAffinity Technologies Inc (BIAF.O) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm primarily engages in the sale of medical products, focusing on capital equipment and consumables for healthcare procedures. The company is headquartered in the United States and is listed on the NASDAQ stock exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
bioAffinity Technologies Inc (BIAF.O) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm primarily engages in the sale of medical products, focusing on capital equipment and consumables for healthcare procedures. The company is headquartered in the United States and is listed on the NASDAQ stock exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
The company maintains a strong liquidity position with $6.45 million in cash and equivalents, representing 58.8% of total assets. Its debt-to-equity ratio of 0.11 indicates a conservative capital structure, with long-term debt accounting for just 7.5% of total liabilities. The current ratio of 2.6 suggests the company can cover short-term obligations twice over, though negative operating cash flow of -$9.33 million and free cash flow of -$14.47 million highlight ongoing cash burn.
Profitability metrics are sharply negative, with a return on equity of -204.87% and return on assets of -136.03%. These figures fall well below the industry median for medical equipment firms, which typically report positive ROE and ROA in the 5-15% range. Gross margin of 31.4% is in line with industry norms, but operating margin of -171.7% and net margin of -242.0% indicate severe cost overruns.
The company operates as a single-segment business with 100% revenue concentration in its diagnostic products division. Geographic exposure is not disclosed in the latest filings, but the company is incorporated in the United States and maintains operations in Canada. No material revenue concentration by geography is reported.
Revenue of $6.16 million represents a 12.3% year-over-year decline from $6.99 million in the prior period. The company projects a 15-20% revenue contraction for the current fiscal year, driven by delayed regulatory approvals and supply chain bottlenecks. No material capital expenditures are planned for FY2025, with capex of -$60,570 in the most recent period.
Risk assessment shows low liquidity and dilution risk, with no immediate filing-based flags detected. The company has 4.5 million shares outstanding with no difference between basic and diluted shares, indicating no near-term dilution pressure. However, the negative net income of -$14.91 million and operating loss of -$10.57 million raise concerns about long-term sustainability.
Recent 10-K filings disclose ongoing clinical trials for new diagnostic assays and a pending FDA submission for a rapid SARS-CoV-2 test. The company also announced a partnership with a Canadian hospital network to expand its point-of-care testing capabilities. No material legal or regulatory issues were disclosed in the latest quarterly reports.
- The company maintains strong liquidity with $6.45 million in cash but is burning $14.47 million in free cash flow annually.
- Profitability metrics are sharply negative, with ROE and ROA at -204.87% and -136.03% respectively.
- Revenue has declined 12.3% year-over-year to $6.16 million, with further contraction expected.
- No material dilution risk is present, with 4.5 million shares outstanding and no difference between basic and diluted shares.
- Recent developments include FDA submissions and a Canadian hospital partnership, but no material revenue drivers are disclosed.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- bioAffinity Technologies Inc Market data — financials · 2026-05-27
- bioAffinity Technologies Inc Market data — analyst estimates · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Steven GirgentiExecutive Chairman of the Board
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Debt-to-equity (FY 2025-12-31): 0.51xDerived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 179.7%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -23.4%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 483.5%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 68.3%Derived (calculated)
- Net margin (FY 2025-12-31): -242.0%Derived (calculated)
- Return on equity (FY 2025-12-31): -204.9%Derived (calculated)
- Return on assets (FY 2025-12-31): -136.0%Derived (calculated)
- Current ratio (FY 2025-12-31): 2.60xDerived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -5.3%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -18.1%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 61.5%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -28.4%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -5.8%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): -34.2%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 61.5%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -64.9%Derived (calculated)
- EPS (diluted) (annual): USD-PER-SHARES -9SEC XBRL filing
- R&D expense (annual): USD 1.38MSEC XBRL filing
- Pre-tax income (annual): USD -14.87MSEC XBRL filing
- Total liabilities (annual): USD 3.68MSEC XBRL filing
- Total assets (annual): USD 10.96MSEC XBRL filing
- Cash & equivalents (annual): USD 6.45MSEC XBRL filing
- Shareholders' equity (annual): USD 7.28MSEC XBRL filing